Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodLenalidomide Promotes the Development of TP53-Mutated Therapy-Related Myeloid Neoplasms

The use of thalidomide analogs, specifically lenalidomide, has been linked to an increased risk of TP53-mutated myeloid neoplasms. Furthermore, lenalidomide, but not pomalidomide, causes the expansion of preleukemic Trp53-mutant HSPCs via selective Ck1 degradation.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form